SecurityUS0153511094 / Alexion Pharmaceuticals, Inc.
InstitutionWealthfront Inc
Latest Disclosed Ownership2,714 shares
Latest Disclosed Value $ 377,000
Wealthfront Inc reports 9.74% decrease in ownership of US0153511094 / Alexion Pharmaceuticals, Inc.

On April 30, 2019 - Wealthfront Inc filed a 13F-HR/A form disclosing ownership of 2,714 shares of Alexion Pharmaceuticals, Inc. (US:US0153511094) valued at $377,000 USD as of September 30, 2018. The entity filed a previous 13F-HR/A on April 30, 2019 disclosing 3,007 shares of Alexion Pharmaceuticals, Inc.. This represents a change in shares of -9.74% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2019-04-30 2018-09-30 13F/A-1 ALEXION PHARMACEUTICALS COM 015351109 2,714 -293 -9.74 377 1.07 0.0036
2019-04-30 2018-06-30 13F/A-1 ALEXION PHARMACEUTICALS COM 015351109 3,007 969 47.55 373 30.42 0.0038
2019-04-30 2017-09-30 13F/A-1 ALEXION PHARMACEUTICALS COM 015351109 2,038 2,038 7.09 286 23.81 0.0037
2017-08-11 2017-06-30 13F ALEXION PHARMACEUTICALS COM 015351109 0 -1,903 -100.00 0 -100.00
2019-05-02 2017-03-31 13F/A-1 ALEXION PHARMACEUTICALS COM 015351109 1,903 -395 -17.19 231 -17.79 0.0041
2019-04-30 2016-12-31 13F/A-1 ALEXION PHARMACEUTICALS COM 015351109 2,298 217 10.43 281 10.20 0.0062
2019-04-30 2016-09-30 13F/A-1 ALEXION PHARMACEUTICALS COM 015351109 2,081 2,081 255 0.0060
2016-05-18 2016-03-31 13F ALEXION PHARMACEUTICALS COM 015351109 0 -2,335 -100.00 0 -100.00
2016-02-17 2015-12-31 13F ALEXION PHARMACEUTICALS COM 015351109 2,335 521 28.72 445 56.69 0.0160
2015-11-18 2015-09-30 13F ALEXION PHARMACEUTICALS COM 015351109 1,814 351 23.99 284 7.58 0.0114
2015-08-18 2015-06-30 13F ALEXION PHARMAC COM 015351109 1,463 -676 -31.60 264 -28.84 0.0109
2015-05-14 2015-03-31 13F ALEXION PHARMAC COM 015351109 2,139 -4 -0.19 371 -6.55 0.0178
2015-02-17 2014-12-31 13F ALEXION PHARMAC COM 015351109 2,143 633 41.92 397 58.80 0.0232
2014-11-14 2014-09-30 13F ALEXION PHARMAC Common 015351109 1,510 257 20.51 250 21.36 0.0173
2014-07-24 2014-06-30 13F ALEXION PHARMAC Common 015351109 1,253 862 220.46 206 237.70 0.0179
2014-05-29 2014-03-31 13F ALEXION PHARMAC Common 015351109 391 391 61 0.0083
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.